Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2025-03-27 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
2024年度利润分配方案
Notice of Dividend Amount Classification · 95% confidence The document is an announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the 2024 annual profit distribution plan. It details the board and supervisory committee's approval of the profit distribution proposal, including cash dividends per share, total dividend amounts, and compliance with relevant regulations. The document does not contain full financial statements or comprehensive financial performance data but focuses on the dividend distribution plan and related approvals. The length is 2821 characters, which is relatively short and consistent with an announcement rather than a full report. This fits the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and details for shareholders.
2025-03-27 Chinese
关于回购注销第三期限制性股票激励计划部分限制性股票的公告
Transaction in Own Shares Classification · 95% confidence The document is an official announcement from Anhui Anke Biological Engineering (Group) Co., Ltd. regarding the repurchase and cancellation of restricted stock under the company's third restricted stock incentive plan. It details the board and supervisory committee approvals, legal opinions, and the impact on share capital. The content focuses on a specific corporate action related to stock repurchase and cancellation of incentive shares, including pricing, reasons, and procedural compliance. There are no financial statements, earnings data, or management discussion of financial results. The document is not a full annual or interim report, nor is it a call transcript or investor presentation. It is a formal announcement of a capital change event (repurchase and cancellation of shares). Therefore, the most appropriate classification is "Transaction in Own Shares (POS)" which covers company buybacks or share repurchases.
2025-03-27 Chinese
2024年年度审计报告
Audit Report / Information Classification · 95% confidence The document is titled '审计报告' which translates to 'Audit Report'. It is issued by a certified accounting firm (容诚会计师事务所) and includes detailed audit opinions, basis for audit opinions, key audit matters, and responsibilities of management and auditors. The document contains comprehensive financial statements including consolidated balance sheets, income statements, cash flow statements, and statements of changes in equity for the fiscal year ending December 31, 2024. The length of the document is substantial (15,000 characters), and it contains actual financial data and detailed audit procedures rather than just an announcement or certification. This matches the definition of an Audit Report / Information (AR) filing, which includes standalone audit reports and applied accounting principles, excluding full annual reports. Although it contains financial statements, the primary focus is the audit report itself, not the full annual report. Therefore, the correct classification is AR with high confidence. FY 2024
2025-03-27 Chinese
独立董事2024年度述职报告（朱卫东）
Board/Management Information Classification · 95% confidence The document is a detailed annual performance report by an independent director of a company, describing their activities, attendance at board and shareholder meetings, audit committee involvement, communication with auditors, and engagement with shareholders during the year 2024. It includes specific references to the director's duties, meetings attended, audit reviews, and governance oversight. The content is focused on the independent director's role and responsibilities rather than financial results or audit opinions alone. This type of document fits best under Board/Management Information (MANG), as it relates to management and board-level reporting on governance and director activities. The document length is 3305 characters, which is consistent with a detailed report rather than a brief announcement or certification. There is no indication that this is an annual report, audit report, or regulatory filing. Therefore, the classification is MANG with high confidence.
2025-03-27 Chinese
2024年度内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It is issued by a certified public accounting firm and addresses the effectiveness of internal controls over financial reporting as of December 31, 2024. The content includes auditor responsibilities, management responsibilities, and an audit opinion on internal control effectiveness. The document is a standalone audit report focused on internal control over financial reporting, not a full annual report or other type of filing. The length is 1426 characters, indicating it is a concise audit report rather than a full annual report or interim report. Therefore, the document fits the definition of an Audit Report / Information (AR). FY 2024
2025-03-27 Chinese
2024年度财务决算报告
Annual Report Classification · 95% confidence The document is titled as a 2024年度财务决算报告, which translates to 2024 Annual Financial Settlement Report. It contains detailed consolidated and parent company financial statements as of December 31, 2024, including balance sheets, income statements, cash flow statements, and notes. The report is audited by an accounting firm with an unqualified opinion. The content includes comprehensive financial data, analysis of asset and liability changes, operating results, and cash flow details for the full fiscal year 2024. The length of the document (6655 characters) and the presence of full financial statements and detailed financial analysis confirm it is a full annual report rather than a brief announcement or certification. Therefore, the document fits the definition of an Annual Report (10-K). FY 2024
2025-03-27 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.